GMED
Globus Medical
NYSE: GMED · HEALTHCARE · MEDICAL DEVICES
$76.68
+0.00% today
Updated 2026-06-05
Market cap
$10.91B
P/E ratio
18.78
P/S ratio
3.52x
EPS (TTM)
$4.28
Dividend yield
—
52W range
$52 – $101
Volume
1.5M
WallStSmart proprietary scores
74
out of 100
Grade: B
Buy
Investment rating
9.3
Growth
A+9.5
Quality
A+7.5
Profitability
B+6.7
Valuation
B6/9
Piotroski F-Score
Moderate
5.4
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$110.00
+43.45%
12-Month target
$90.01
+17.38%
Intrinsic (DCF)
$138.77
Margin of safety
+36.40%
3 Strong Buy6 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 5.43 — safe zone
+ Free cash flow $162.75M — positive
+ Revenue growth 27.00% QoQ
+ 36.40% below intrinsic value
+ Debt/equity 0.02x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.02B | $1.57B | $2.52B | $2.94B | $3.10B |
| Net income | $190.17M | $122.87M | $102.98M | $537.90M | $124.30M |
| EPS | — | — | — | — | $4.28 |
| Free cash flow | $104.42M | $165.22M | $405.21M | $588.77M | $162.75M |
| Profit margin | 18.59% | 7.83% | 4.09% | 18.30% | 18.90% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-25 | HULLER, KELLY | Sale | 20,000 | — |
| 2026-02-25 | HULLER, KELLY | Buy | 20,000 | $43.58 |
| 2026-02-12 | HULLER, KELLY | Sale | 10,000 | — |
Peer comparison
Smart narrative
Globus Medical trades at $76.68. representing a P/E of 18.78x trailing earnings. Our Smart Value Score of 74/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 5.43, it sits in the safe zone. TTM revenue stands at $3.10B. with profit margins at 18.90%. Our DCF model estimates intrinsic value at $138.77.
Frequently asked questions
What is Globus Medical's stock price?
Globus Medical (GMED) trades at $76.68, on a P/E of 18.8x and a P/S of 3.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Globus Medical overvalued?
Globus Medical carries a Smart Value Score of 74/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $138.77 versus the $76.68 price, a 36.4% margin of safety on a cash flow basis.
What is the price target of Globus Medical (GMED)?
The 12-month analyst consensus target is $110.00, about 43.5% above the current $76.68. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Globus Medical (GMED)?
Our DCF model estimates intrinsic value at $138.77, a +36.4% margin of safety versus today's $76.68. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Globus Medical's revenue?
Globus Medical's trailing twelve-month revenue is $3.10B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Globus Medical's Altman Z-Score is 5.43, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.52x
ROE12.40%
Beta0.95
50D MA$85.95
200D MA$80.58
Shares out0.11B
Float0.11B
Short ratio—
Avg volume1.5M
Performance
1 week-14.83%
1 month-15.20%
3 months-13.57%
YTD-12.18%
1 year—
3 years—
5 years—